First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) Inhibitor, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 77-86

  Sarker, Debashis ^a,b   Ang, Joo Ern ^a,b   Baird, Richard ^a,b   Kristeleit, Rebecca ^a,b   Shah, Krunal ^a,b   Moreno, Victor ^a,b   Clarke, Paul A ^b   Raynaud, Florence I ^b   Levy, Gallia ^c   Ware, Joseph A ^c   Mazina, Kathryn ^c   Lin, Ray ^c   Wu, Jenny ^c   Fredrickson, Jill ^c   Spoerke, Jill M ^c   Lackner, Mark R ^c   Yan, Yibing ^c   Friedman, Lori S ^c   Kaye, Stan B ^a,b   Derynck, Mika K ^c   Workman, Paul ^b   De Bono, Johann S ^a,b   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EMOLLIENT AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PICTILISIB; PLATINUM COMPLEX; PREDNISOLONE; PROTEIN KINASE B; S6 KINASE; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; B RAF KINASE; BRAF PROTEIN, HUMAN; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ACIDOSIS; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DECREASED APPETITE; DIARRHEA; DIET RESTRICTION; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; ELECTROCARDIOGRAPHY; ENZYME PHOSPHORYLATION; FATIGUE; FEMALE; GENE; GENE AMPLIFICATION; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIVER METASTASIS; LOW DRUG DOSE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MIDDLE AGED; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; OVARY CANCER; OVARY CARCINOMA; PANCREATICODUODENECTOMY; PAPULAR RASH; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PIK3CA GENE; PLATELET-RICH PLASMA CELL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN DEPLETION; RASH; RECOMMENDED DRUG DOSE; REFRACTORY PERIOD; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; STOMATITIS; TANDEM MASS SPECTROMETRY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; XERODERMA; YOUNG ADULT; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; GENETICS; MAXIMUM TOLERATED DOSE; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INDAZOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84920538174     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0947     Document Type: Article

References (36)

1. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges M. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329-41.
2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
3. Clarke PA, Workman P. Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J Clin Oncol 2012;30:331-3.
4. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009;37:217-22.
5. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63.
6. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
7. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
8. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51:5522-32.
9. Raynaud FI, Eccles SA, Patel S, Alix S, Baker SJ, Box G, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 2009;8:1725-38.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
11. Chanock SJ, Burdett L, Yeager M, Llaca V, Langerod A, Presswalla S, et al. Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res 2007;9:R5.
12. Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J, et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol 2012;25:902-10.
13. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21:419-23.
14. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10:143-53.
15. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-90.
16. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011;29:4688-95.
17. Workman P. How much gets there and what does it do?: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9: 891-902.
18. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10:514-23.
19. Dean E, Greystoke A, Ranson M, Dive C. Biomarkers of cell death applicable to early clinical trials. Exp Cell Res 2012;318:1252-9.
20. Hait WN. Forty years of Translational Cancer Research. Cancer Discov 2011;1:383-390.
21. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010;70: 2146-57.
22. Powis G, Ihle N, Kirkpatrick DL. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 2006;12:2964-6.
23. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006;441:366-70.
24. Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legeux M, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther 2012;11:1747-57.
25. Salphati L, Lee LB, Pang J, Plise EG, Zhang X. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010;38: 1422-6.
26. Bruning JC, Gautam D, Burks DJ, Gilette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-5.
27. Okamoto H, Nakae J, Kitamura T, Park BC, Dragastis I, Accili D. Transgenic rescue of insulin receptor-deficient mice. J Clin Invest 2004;114:214-23.
28. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002;8: 1376-82.
29. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014 20:233-45.
30. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012;18:4173-82.
31. Ma WW, Jacene H, Song D, Vilardelli F, Messersmith WA, Laheru D, et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27:2697-704.
32. Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, et al. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer 2014;13:83.
33. Ali K, Soond DR, Piñeiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014;510:407-11.
34. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15:429-40.
35. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerroero S, Jung K, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15:4649-64.
36. Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009;15:4147-56.